FY2027 EPS Estimates for Immunocore Boosted by HC Wainwright

Key Points

• HC Wainwright has raised its FY2027 EPS forecast for Immunocore from $1.10 to $1.12 and maintains a "Buy" rating with a target price of $100.00.
• Immunocore recently reported a quarterly earnings performance of -$0.20 EPS, surpassing analyst expectations, with a revenue of $130.65 million, reflecting a 30% year-over-year increase.
• Institutional investors control 84.50% of Immunocore, with significant recent activity from various hedge funds increasing their stakes in the company.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) - Stock analysts at HC Wainwright upped their FY2027 earnings per share estimates for Immunocore in a research note issued on Tuesday, August 12th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of $1.12 per share for the year, up from their prior estimate of $1.10. HC Wainwright currently has a "Buy" rating and a $100.00 target price on the stock. The consensus estimate for Immunocore's current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunocore's FY2029 earnings at $7.88 EPS.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.01. The firm had revenue of $130.65 million during the quarter, compared to analyst estimates of $122.96 million. Immunocore had a negative return on equity of 5.40% and a negative net margin of 5.70%. Immunocore's quarterly revenue was up 30.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.23) earnings per share.

IMCR has been the subject of several other reports. Deutsche Bank Aktiengesellschaft assumed coverage on Immunocore in a report on Tuesday, May 27th. They set a "buy" rating and a $65.00 target price for the company. Wall Street Zen downgraded Immunocore from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Oppenheimer boosted their price objective on Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $58.00.

Immunocore Stock Down 1.7%

Immunocore stock traded down $0.57 during midday trading on Wednesday, hitting $32.31. The stock had a trading volume of 193,900 shares, compared to its average volume of 337,789. The company has a current ratio of 5.89, a quick ratio of 5.86 and a debt-to-equity ratio of 1.01. The stock has a market cap of $1.63 billion, a P/E ratio of -80.78 and a beta of 0.77. Immunocore has a 12 month low of $23.15 and a 12 month high of $39.33. The business has a fifty day moving average price of $33.60 and a 200 day moving average price of $31.24.

Institutional Investors Weigh In On Immunocore

A number of institutional investors have recently added to or reduced their stakes in IMCR. GF Fund Management CO. LTD. acquired a new stake in shares of Immunocore during the 4th quarter valued at $25,000. Caitong International Asset Management Co. Ltd boosted its holdings in Immunocore by 4,696.3% in the second quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company's stock worth $41,000 after purchasing an additional 1,268 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new stake in Immunocore during the second quarter valued at about $42,000. State of Tennessee Department of Treasury bought a new stake in Immunocore during the second quarter valued at about $132,000. Finally, Oppenheimer Asset Management Inc. bought a new stake in shares of Immunocore in the first quarter valued at about $225,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.